相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Vaxess Technologies presented preclinical data showing their microarray patch delivers semaglutide with bioavailability comparable to subcutaneous injection in Gottingen minipigs. - The needle-free, self-applied patch achieved modestly higher Cmax with similar half-life profiles using a clinically-relevant 2 nmol/kg dose. - The company secured $9 million in additional funding from RA Capital Management and Engine Ventures to advance GLP-1 development and expand manufacturing capabilities. - Vaxess has partnered with a leading biopharma company to evaluate diabetes and obesity therapeutics delivery through their room-temperature stable patch platform.
- The Diabetes Prevention Program (DPP) demonstrated that lifestyle interventions and metformin can prevent or delay type 2 diabetes in high-risk individuals. - The DPP Outcomes Study (DPPOS) has shown that the benefits of lifestyle changes and metformin persist for at least 15 years, reducing the risk of developing type 2 diabetes. - The DPPOS is now focusing on whether metformin can reduce the rates of cardiovascular diseases and cancer in people at high risk for type 2 diabetes. - Modified versions of the DPP Lifestyle Change Program are now widely available and covered by Medicare, increasing accessibility for at-risk individuals.
- A NIH study reveals that adolescents undergoing bariatric surgery maintain significant weight loss and comorbidity remission 10 years post-procedure. - Participants experienced an average 20% reduction in BMI and significant reductions in type 2 diabetes, hypertension, and abnormal cholesterol. - The remission rate for type 2 diabetes was notably higher in adolescents (55%) compared to adults undergoing similar procedures. - The Teen Longitudinal Assessment of Bariatric Surgery (Teen LABS) highlights the durable health benefits of early bariatric intervention.
- The NIH has initiated a nationwide study to address the increasing rates of type 2 diabetes among young individuals, aiming to improve prevention and treatment strategies. - The study will recruit 3,600 participants aged 9-14 at risk for type 2 diabetes, focusing on diverse racial, ethnic, and socioeconomic backgrounds to reflect the affected population. - Researchers will investigate biological, social, and environmental factors contributing to youth-onset type 2 diabetes to identify at-risk children and tailor interventions. - The DISCOVERY study seeks input from youth, young adults, and parents with lived experience to optimize study design and ensure relevance to affected communities.
